A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL

Clinical trial NCT06220487 · RECRUITING

Trial details

NCT number: NCT06220487
Sponsor: Nanfang Hospital, Southern Medical University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia Philadelphia Chromosome Philadelphia-Positive ALL Adult ALL IKZF1 Gene Mutation

Start date: 2024-02-01
Primary completion: 2025-12-31
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.